Quick-and-Early IVIG Therapy: Hints of Promise? Anti-Amyloid Results Show Modest Benefits, Mild Side Effects Wrapping Up Enrollment, ADNI 2, PPMI Focus on Earlier Disease Drug Data Dash at AAN Annual Conference The ANN conference in San Diego covered such
Exploring Genome Fragmentation in Neurodegeneration Up-and-Coming ALS Mice Leave Scientists ConFUSed Does ALS Gene Police RNA, Keep Strands From Entangling? Does New Amyloid Protein Lend Tau a Hand? Keystone Symposium: New Frontiers in Neurodegenerative D
Microglia Activation—Venusberg Meeting Questions M1, M2 Designations Inflammatory Crosstalk Between Periphery and Brain Blessing or Curse? Peripheral Cytokines in the Brain Glial Imaging—Amid Slow Progress, EU Project Takes Up Challenge Venusberg Meeting
Combination Drug Trials: Time to Open a New Front in AD? Combination Trials: FDA Puts Flesh on Bones of Draft Guidance Combination Trials: Companies Can Play Well in One Sandbox Building a Roadmap for Shared Combination Drug Trials ACT-AD FDA/AD Allies Me
Keystone Symposia Meeting, Part 1—Alzheimer’s Disease: Genes, Cellular Pathways and Therapies Keystone Symposia Meeting, Part 2—Genetics and Epidemiology of AD Keystone Symposia Meeting, Part 3—Amyloid Precursor Protein Function Keystone Symposia Meeting,
Many researchers believe that neurodegeneration's takeover of one's brain might be driven by pathogenic, misfolded proteins spreading through interconnected neural networks...